Grifols (NASDAQ:GRFS) Shares Climb 7.2% - Here's Why

Key Points

• Grifols shares rose 7.2% to $8.1050, although trading volume was about 70% below the average session volume.
• Analyst sentiment remains cautious: JPMorgan cut its price target to $9 and maintained a neutral rating, while the overall consensus rating is “Reduce” with a $9.00 target.
• Several institutional investors increased their Grifols holdings recently, including Quadrant Capital Group, which boosted its stake by 217.4% during the third quarter.

Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s stock price rose 7.2% on Monday. The company traded as high as $8.01 and last traded at $8.1050. 192,511 shares traded hands during trading, a decline of 70% from the average session volume of 636,375 shares. The stock had previously closed at $7.56.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on GRFS shares. Weiss Ratings raised shares of Grifols from a "sell (d)" rating to a "sell (d+)" rating in a research note on Monday, August 17th. Wall Street Zen lowered Grifols from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. Zacks Research upgraded Grifols from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. lowered their price target on Grifols from $10.00 to $9.00 and set a "neutral" rating for the company in a research report on Monday. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average target price of $9.00.

Grifols Price Performance

The company has a 50-day moving average price of $7.58 and a two-hundred day moving average price of $7.71. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81. The company has a market cap of $5.38 billion, a PE ratio of 41.55, a P/E/G ratio of 0.28 and a beta of 0.70.

Hedge Funds Weigh In On Grifols

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC boosted its holdings in shares of Grifols by 68.7% during the third quarter. Signaturefd LLC now owns 4,372 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 1,781 shares during the period. Quadrant Capital Group LLC boosted its stake in Grifols by 217.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 35,155 shares of the biotechnology company's stock valued at $252,000 after purchasing an additional 24,080 shares during the period. GAMMA Investing LLC boosted its stake in Grifols by 41.1% during the 3rd quarter. GAMMA Investing LLC now owns 6,588 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 1,918 shares during the period. Financial Symmetry Inc bought a new position in Grifols in the 3rd quarter worth about $73,000. Finally, QRG Capital Management Inc. grew its position in Grifols by 10.6% in the 2nd quarter. QRG Capital Management Inc. now owns 48,218 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 4,604 shares during the last quarter.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.